CLINICAL TRIAL UPDATE

Glyco FLEX® 3 Dog Study Published
In a randomized, double-blind, crossover design dog study, a stifle osteoarthritis (OA) model was used to determine if Glyco FLEX® 3 could reduce cartilage breakdown and help normalize joint function. The dogs were randomized into two groups, the treatment dogs (Glyco FLEX® 3) and the control group. After a wash-out period, the two groups were crossed over for treatment and control. Force plate analysis was performed on each of the dogs. Then synovial fluid was collected from the stifle joint and analyzed for markers of joint inflammation and degradation. The responders had significant improvement in lameness after treatment, with a 41% increase in Peak Vertical Force (PVF) and 44% increase in Vertical Impulse (VI) over the pre-treatment value in the dogs. There was a significant decrease in mean synovial PGE2 and soluble collagen (SC) levels in the treatment group as compared to the control group. Other synovial markers in the responders had trends for lower levels, compared to the control group. The results of the study support that Glyco FLEX® 3 may reduce the severity of cartilage breakdown and synovitis, and help normalize joint function in dogs with stifle joints affected by OA.

For additional research on the active ingredients in Glyco FLEX® 3 please refer to VetriScience®’s Clinical & Research Studies Guide reference #’s: VSL 100; VSL 110; VSL 200; VSL 210; VSL 220; VSL 230; VSL 240; VSL 250; VSL 260; VSL 270; VSL 280.

**SUMMARY**

> Glyco FLEX® 3 may reduce the severity of cartilage breakdown and synovitis, and help normalize joint function in osteoarthritic stifle joints.

> The results of this in vivo (VSL 120) study more than correlate/parallel those from other in vitro (VSL 130 and VSL 260) studies.

**SUMMARY**

> When used on a canine-specific cartilage cell line, Glyco FLEX® 3 appears to have anti-inflammatory and antioxidant properties.

> Glyco FLEX® 3 appears to reduce cartilage breakdown, inhibit cytokine-induced NO and PGE2 production, and reduce proteolytic breakdown.

> Results from this in vitro (VSL 130) study more than correlate/parallel other in vitro (VSL 260) and in vivo (VSL 120) studies.

For more information on Glyco FLEX®, please visit us at www.vetriscience.com